Physician profile
Christopher M Mcgonnell
NPI 1437101136
$1,451.12
in general payments reported to CMS, 2019-2025
20 companies · $265 in 2025
The $265 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $58.39 · 2021: $187 · 2022: $274 · 2023: $173 · 2024: $225 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $252.88 | 2019-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $200.32 | 2019-2025 | Doc Band |
| Corium, LLC | $158.15 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $101.56 | 2019-2024 | Cotempla Xr-Odt |
| Ironshore Pharmaceuticals INC. | $98.37 | 2022-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $82.31 | 2019-2021 | |
| Sanofi Pasteur INC. | $77.69 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $75.84 | 2024-2025 | |
| Glaxosmithkline, LLC. | $68.29 | 2019-2023 | Bexsero |
| Merck Sharp & Dohme LLC | $61.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2023 | Flumist Quadrivalent |
| Pfizer INC. | $37.03 | 2022-2024 | |
| Shire North American Group INC | $36.32 | 2019 | |
| Collegium Pharmaceutical, INC. | $28.70 | 2025 | Jornay Pm |
| Genentech USA, INC. | $27.42 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $26.77 | 2022 | |
| Sobi, INC | $22.90 | 2019 | |
| Seqirus USA INC | $19.11 | 2024 | Flucelvax |
| Vertical Pharmaceuticals, LLC | $18.73 | 2025 | Relexxii |
| Lnhc, INC | $14.47 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mcgonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.